Get the Stockscreener App
1.51
4.35%
0.06
Salarius Pharmaceuticals Inc stock is traded at $1.51, with a volume of 12,603.
It is up +4.35% in the last 24 hours and up +7.31% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$1.45
Open:
$1.45
24h Volume:
12,603
Relative Volume:
0.02
Market Cap:
$2.09M
Revenue:
$4.70M
Net Income/Loss:
$-12.54M
P/E Ratio:
-0.1178
EPS:
-12.82
Net Cash Flow:
$-12.85M
1W Performance:
-10.99%
1M Performance:
+7.31%
6M Performance:
-62.25%
1Y Performance:
-76.43%
1-Day Range:
$1.45
$1.53
1-Week Range:
$1.38
$1.7455
52-Week Range:
$1.26
$7.44
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Salarius Pharmaceuticals (FRA:FP10) Intrinsic Value: Projec - GuruFocus.com
SLRX Stock Update: Salarius Pharmaceuticals Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
SLRX stock touches 52-week low at $1.3 amid market challenges - Investing.com India
SLRX stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
SLRX stock touches 52-week low at $1.34 amid market challenges - Investing.com India
SLRX stock touches 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals sets date for 2024 Annual Meeting By Investing.com - Investing.com Canada
Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Quotes, Forecast and News Summary - Benzinga
Salarius Pharmaceuticals sets date for 2024 Annual Meeting - Investing.com
Sasol Limited (SSL): Among the Worst Affordable Stocks to Buy Under $10 - Yahoo Finance UK
Ready to Jump After Recent Trade: SELLAS Life Sciences Group Inc (SLS) - SETE News
2,100 Shares in Silicon Laboratories Inc. (NASDAQ:SLAB) Bought by MQS Management LLC - Defense World
Rhumbline Advisers Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Silence Therapeutics plc (NASDAQ:SLN) is M28 Capital Management LP's 6th Largest Position - MarketBeat
Strategic Education, Inc. (NASDAQ:STRA) Holdings Raised by Dimensional Fund Advisors LP - Defense World
Safire Group Raises $8M in Financing - FinSMEs
Drugmaker for rare disease soars 1,200% in last year - Kursiv Media
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 52-Week High at $54.32 - MarketBeat
Saala gets an OTT release date - Cinema Express
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.7% - Defense World
Salarius Pharmaceuticals registers new shares for offering By Investing.com - Investing.com Australia
Salarius Pharmaceuticals registers new shares for offering - Investing.com India
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q2 2024 - InvestorPlace
The Future of Salarius Pharmaceuticals Inc: Analyzing SLRX - The InvestChronicle
Salarius: Q2 Earnings Snapshot - San Antonio Express-News
Salarius Pharmaceuticals Inc (SLRX)’s Day in Review: Closing at 2.06, Down by -12.71 - The Dwinnex
Take off with Salarius Pharmaceuticals Inc (SLRX): Get ready for trading - SETE News
The Significance of Moving Averages in Salarius Pharmaceuticals Inc Inc. (SLRX) Price Performance - The InvestChronicle
Understanding SLRX stock ratios for better investment decisions - US Post News
Market Insights: Salarius Pharmaceuticals Inc (SLRX)’s Notable Drop of -11.53, Closing at 3.30 - The Dwinnex
Salarius Pharmaceuticals Inc [SLRX] Revenue clocked in at $0.00 million, down -28.27% YTD: What’s Next? - The DBT News
Salarius Pharmaceuticals Inc (SLRX Stock: A Sea of Opportunity - The InvestChronicle
Market Insights: Salarius Pharmaceuticals Inc (SLRX)’s Notable Gain of 63.55, Closing at 3.50 - The Dwinnex
Salarius Pharmaceuticals Registers New Stock Offering By Investing.com - Investing.com Canada
Salarius Pharmaceuticals Registers New Stock Offering - Investing.com
Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal
Holdings of Salarius Pharmaceuticals Inc (SLRX) are aligned with the stars - SETE News
Salarius Pharmaceuticals (SLRX) drops 21% and here’s why - BP Journal
Azitra (AZTR) Makes Strides with New Patents and Public Offering - BP Journal
Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today? - InvestorPlace
Salarius Pharmaceuticals registers new stock offering - Investing.com India
Salarius Pharmaceuticals registers new stock offering By Investing.com - Investing.com Canada
Salarius Pharmaceuticals Inc (SLRX) is a good investment, but the stock may be undervalued - US Post News
MEIP Stock sees a Significant Surge Amidst Strategic Evaluation - BP Journal
Will MIRA Pharmaceuticals MIRA Stock Keep Surging further on Promising Preclinical Data for Ketamir-2 - BP Journal
Salarius Pharmaceuticals Inc Inc. (SLRX) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket - Benzinga
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Salarius Pharma falls on ending early-stage bone cancer study - XM
Salarius Pharmaceuticals ends Ewing sarcoma trial - Investing.com India
It is Poised to be a Bull Market for Salarius Pharmaceuticals Inc (SLRX) - SETE News
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):